Outcome of MICB-52Asp patients according to donor MICA-STR–match status and NKG2D-72 genotype
| Donor STR match status/donor NKG2D-72 residue genotype . | Number . | Overall mortality HR (95% CI; P value) . | Relapse HR (95% CI; P value) . | Disease-free survival HR (95% CI; P value) . |
|---|---|---|---|---|
| Matched/Ala | 286 | 1.0 | 1.0 | 1.0 |
| Matched/AlaThr | 162 | 1.30 (0.97-1.74; .08) | 1.09 (0.77-1.53; .63) | 1.12 (0.85-1.48; .41) |
| Matched/Thr | 30 | 0.65 (0.31-1.34; .24) | 0.56 (0.24-1.31; .18) | 0.55 (0.27-1.14; .11) |
| Mismatched/Ala | 331 | 0.79 (0.60-1.03; .08) | 0.89 (0.66-1.18; .41) | 0.83 (0.65-1.05; .12) |
| Mismatched/AlaThr | 226 | 0.88 (0.66-1.18; .40) | 0.99 (0.73-1.34; .95) | 0.93 (0.72-1.20; .57) |
| Mismatched/Thr | 34 | 0.53 (0.25-1.10; .09) | 0.40 (0.17-0.93; .03) | 0.58 (0.32-1.07; .08) |
| Donor STR match status/donor NKG2D-72 residue genotype . | Number . | Overall mortality HR (95% CI; P value) . | Relapse HR (95% CI; P value) . | Disease-free survival HR (95% CI; P value) . |
|---|---|---|---|---|
| Matched/Ala | 286 | 1.0 | 1.0 | 1.0 |
| Matched/AlaThr | 162 | 1.30 (0.97-1.74; .08) | 1.09 (0.77-1.53; .63) | 1.12 (0.85-1.48; .41) |
| Matched/Thr | 30 | 0.65 (0.31-1.34; .24) | 0.56 (0.24-1.31; .18) | 0.55 (0.27-1.14; .11) |
| Mismatched/Ala | 331 | 0.79 (0.60-1.03; .08) | 0.89 (0.66-1.18; .41) | 0.83 (0.65-1.05; .12) |
| Mismatched/AlaThr | 226 | 0.88 (0.66-1.18; .40) | 0.99 (0.73-1.34; .95) | 0.93 (0.72-1.20; .57) |
| Mismatched/Thr | 34 | 0.53 (0.25-1.10; .09) | 0.40 (0.17-0.93; .03) | 0.58 (0.32-1.07; .08) |
Patients with MICB-52Asp who received a transplant from a MICA-STR–mismatched, NKG2D-72Thr donor have lower risk of relapse after transplantation compared with patients who received a transplant from a MICA-STR–matched, NKG2D-72Ala donor.